Lantheus (NASDAQ:LNTH) issued its quarterly earnings results on Tuesday. The medical equipment provider reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06, MarketWatch Earnings reports. Lantheus had a return on equity of 11.05% and a net margin of 0.12%. The company had revenue of $92.51 million during the quarter, compared to analyst estimates of $87.24 million. During the same period in the previous year, the company earned $0.36 earnings per share. The company’s quarterly revenue was up 2.0% compared to the same quarter last year.

Lantheus stock traded up $0.06 during mid-day trading on Tuesday, hitting $23.74. The stock had a trading volume of 2,232 shares, compared to its average volume of 551,996. Lantheus has a 12 month low of $10.52 and a 12 month high of $24.20. The stock has a 50-day simple moving average of $21.19 and a two-hundred day simple moving average of $16.69. The company has a current ratio of 2.25, a quick ratio of 1.79 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $1.59 billion, a PE ratio of 297.41 and a beta of 1.32.

A number of brokerages have recently commented on LNTH. SVB Leerink upped their price target on Lantheus from $26.00 to $31.00 and gave the stock an “outperform” rating in a report on Tuesday. Credit Suisse Group upped their target price on Lantheus from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Thursday, March 4th. Finally, Zacks Investment Research upgraded Lantheus from a “sell” rating to a “hold” rating in a research note on Wednesday, April 28th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $25.67.

In related news, Director Sam R. Leno sold 5,000 shares of the company’s stock in a transaction dated Thursday, April 8th. The shares were sold at an average price of $21.17, for a total value of $105,850.00. Following the transaction, the director now directly owns 40,784 shares in the company, valued at $863,397.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael P. Duffy sold 7,500 shares of Lantheus stock in a transaction dated Friday, April 16th. The stock was sold at an average price of $21.75, for a total transaction of $163,125.00. Following the completion of the sale, the senior vice president now owns 109,472 shares of the company’s stock, valued at approximately $2,381,016. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 72,188 shares of company stock worth $1,411,148. 2.08% of the stock is currently owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation.

Read More: EV Stocks

Earnings History for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.